Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blind, Phase III Clinical Trial of Neoadjuvant Chemotherapy With Atezolizumab or Placebo in Patients With Triple-Negative Breast Cancer Followed by Adjuvant Continuation of Atezolizumab or Placebo

NCT03281954 is registered in ClinicalTrials.gov with NSABP Foundation Inc as lead sponsor.

NCT NCT03281954
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03281954 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blind, Phase III Clinical Trial of Neoadjuvant Chemotherapy With Atezolizumab or Placebo in Patients With Triple-Negative Breast Cancer Followed by Adjuvant Continuation of Atezolizumab or Placebo
Lead sponsor
NSABP Foundation Inc
Phase
Phase 3
Overall status
Active, not recruiting
Start date
December 19, 2017
Completion date
November 30, 2027
Enrollment
1,550 (actual)
Sites
217

Conditions

As the registry lists them; a condition with its own page is linked.

triple negative breast cancer